Abstract
It is well accepted that inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is one of high risk factors for colorectal cancer (CRC). This supports the notion that inflammation plays a key role in cancer development. Epidemiologic studies have shown that vitamin D (Vit D) deficiency is associated with IBD and various types of cancer including colorectal cancer. Clinical trials and mouse models have shown that Vit D is beneficial in preventing or ameliorating inflammation and carcinogenesis. Mechanism studies show that Vit D played wide-spectrum roles in anti-inflammation, immunoregulation, and anti-cancer activities. In this review, we summarized and updated the findings on Vit D, IBD and colitis-associated colorectal cancer (CAC) with the emphasis on the effects of Vit D on anti-inflammation, EMT and cancer stem cells (CSC).
Keywords: Vitamin D, IBD, colitis-associated colorectal cancer, inflammation, NF-κ B, EMT, cancer stem cell.
Current Medicinal Chemistry
Title:Possible Molecular Mechanisms by which Vitamin D Prevents Inflammatory Bowel Disease and Colitis-associated Colorectal Cancer
Volume: 24 Issue: 9
Author(s): Zijian Luan, Yiming Ma, Yu Xin, Jiaming Qian*Hongying Wang*
Affiliation:
- Department of Gastroenterology, Peking Union Medical College Hospital, Beijing,China
- The State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing,China
Keywords: Vitamin D, IBD, colitis-associated colorectal cancer, inflammation, NF-κ B, EMT, cancer stem cell.
Abstract: It is well accepted that inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is one of high risk factors for colorectal cancer (CRC). This supports the notion that inflammation plays a key role in cancer development. Epidemiologic studies have shown that vitamin D (Vit D) deficiency is associated with IBD and various types of cancer including colorectal cancer. Clinical trials and mouse models have shown that Vit D is beneficial in preventing or ameliorating inflammation and carcinogenesis. Mechanism studies show that Vit D played wide-spectrum roles in anti-inflammation, immunoregulation, and anti-cancer activities. In this review, we summarized and updated the findings on Vit D, IBD and colitis-associated colorectal cancer (CAC) with the emphasis on the effects of Vit D on anti-inflammation, EMT and cancer stem cells (CSC).
Export Options
About this article
Cite this article as:
Luan Zijian, Ma Yiming, Xin Yu, Qian Jiaming*, Wang Hongying*, Possible Molecular Mechanisms by which Vitamin D Prevents Inflammatory Bowel Disease and Colitis-associated Colorectal Cancer, Current Medicinal Chemistry 2017; 24 (9) . https://dx.doi.org/10.2174/0929867323666161202153028
DOI https://dx.doi.org/10.2174/0929867323666161202153028 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) and Microsatellite Instability in Patients with Colorectal Cancer and Its Clinical Features
Current Molecular Medicine Synergistic Antitumor Effect of 5-Fluorouracil Combined with Constituents from <i>Pleurospermum lindleyanum</i> in Hepatocellular Carcinoma SMMC-7721 Cells
Anti-Cancer Agents in Medicinal Chemistry Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery HDAC Inhibitors-New Generation of Target Specific Treatment
Mini-Reviews in Medicinal Chemistry Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
Current Drug Targets The CLCA Gene Family: Putative Therapeutic Target for Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Current Status and Future Perspective for Research on Medicinal Plants with Anticancerous Activity and Minimum Cytotoxic Value
Current Drug Targets Comparative Proteomic Profiling of Extracellular Proteins between Normal and Gastric Cancer Cells
Current Cancer Drug Targets Adenocarcinoma of the Appendix in Elderly: Diagnostic Dilemma
New Emirates Medical Journal Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents The Potential Prebiotic Effects of Yacon (<i>Smallanthus sonchifolius</i>) in Colorectal Cancer
Current Nutrition & Food Science Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma
Current Cancer Drug Targets RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry Nanocrystalline ZnO: A Competent and Reusable Catalyst for the Preparation of Pharmacology Relevant Heterocycles in the Aqueous Medium
Current Green Chemistry Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Bioengineered 3D Scaffolds in Cancer Research: Focus on Epithelial to Mesenchymal Transition and Drug Screening
Current Pharmaceutical Design The Role of Survivin for Radiation Oncology: Moving Beyond Apoptosis Inhibition
Current Medicinal Chemistry